IL-12 enhancement of immune responses to T-independent antigens
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Aug 8, 2001
filing date -
Mar 5, 1998
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to a method of modulating an immune response to a T-cell or thymus independent antigen in a host (e.g., mammalian, including human), comprising administering to the host an effective amount of interleukin-12 (IL-12) and the T-cell independent antigen. In one embodiment, the present invention relates to a method of inducing an immune response to a TI antigen in a host (e.g., mammalian, including human), which comprises administering to the host an effective amount of interleukin-12 (IL-12) and the TI antigen. In another embodiment, the present invention relates to a method of enhancing an immune response against a TI antigen in a host, which comprises administering to the host an effective amount of IL-12 and the TI antigen. The methods of the present invention can be used, for example, to induce and or enhance a humoral immune response (IgG2a and/or IgG3 humoral immune response).
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully